Microbial metabolite restores liver health by targeting PPARα and lipid metabolism through the gut-liver axis
By
PaulHoule
Fresh out the oven, still warm. Top of the tray.
Summary
This scientific research article reports on the therapeutic potential of a microbial metabolite (10-hydroxy-10-hydr) in alleviating liver injury by restoring hepatic lipid metabolism through PPARα signaling across the gut-liver axis. The study highlights how chronic liver diseases like steatosis and fibrosis involve PPARα dysregulation and lipid metabolism disruption, along with gut barrier dysfunction and microbial dysbiosis. The research explores a transformative therapeutic approach that simultaneously targets both the liver and gut, addressing the compromised gut-liver axis in infectious and non-infectious liver diseases.
Key quotes
· 4 pulledInfectious and non-infectious liver diseases are marked by disrupted liver metabolism and are frequently accompanied by gut epithelial barrier dysfunction and microbial dysbiosis, reflecting the compromised gut-liver axis.
Despite the pivotal role of the gut-liver axis in health, transformative therapeutic interventions that simultaneously target both the liver and gut remain underexplored.
Peroxisome proliferator-activated receptor alpha (PPARα) suppression drives both gut and liver metabolic diseases.
Chronic liver diseases, including liver steatosis and fibrosis, are driven in part by dysregulation of PPARα and lipid metabolism.
You might also wanna read
Medical exposure rapidly restructures gut microbiomes in remote Amazonian Indigenous communities
This study examines microbiome changes in remote Amazonian Indigenous communities (335 Amerindians across multiple villages) during the intr
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·54m ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·1h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·4h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·6h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h ago